- Home
- GHC vs RNA Comparison
GHC vs RNA Comparison
Compare GHC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHC
- RNA
- Stock Information
- Founded
- GHC 1877
- RNA 2012
- Country
- GHC United States
- RNA United States
- Employees
- GHC N/A
- RNA N/A
- Industry
- GHC Other Consumer Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- GHC Real Estate
- RNA Health Care
- Exchange
- GHC Nasdaq
- RNA Nasdaq
- Market Cap
- GHC 4.0B
- RNA 3.4B
- IPO Year
- GHC N/A
- RNA 2020
- Fundamental
- Price
- GHC $978.62
- RNA $28.69
- Analyst Decision
- GHC
- RNA Strong Buy
- Analyst Count
- GHC 0
- RNA 12
- Target Price
- GHC N/A
- RNA $68.25
- AVG Volume (30 Days)
- GHC 26.3K
- RNA 1.5M
- Earning Date
- GHC 04-30-2025
- RNA 05-20-2025
- Dividend Yield
- GHC 0.74%
- RNA N/A
- EPS Growth
- GHC 134.95
- RNA N/A
- EPS
- GHC 141.53
- RNA N/A
- Revenue
- GHC $4,804,157,000.00
- RNA $10,897,000.00
- Revenue This Year
- GHC $3.15
- RNA N/A
- Revenue Next Year
- GHC $6.52
- RNA $135.33
- P/E Ratio
- GHC $6.89
- RNA N/A
- Revenue Growth
- GHC 5.91
- RNA 13.98
- 52 Week Low
- GHC $683.00
- RNA $21.51
- 52 Week High
- GHC $1,003.53
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- GHC 63.04
- RNA 47.66
- Support Level
- GHC $928.37
- RNA $25.58
- Resistance Level
- GHC $949.82
- RNA $33.62
- Average True Range (ATR)
- GHC 19.26
- RNA 2.15
- MACD
- GHC 7.63
- RNA -0.23
- Stochastic Oscillator
- GHC 97.71
- RNA 38.72
About GHC Graham Holdings Company
Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.